Search
Abrocitinib
go.drugbank.com/drugs/DB14973ApprovedInvestigationalAbrocitinib is an oral small-molecule inhibitor of Janus kinase 1 (JAK1). Janus kinases are intracellular enzymes involved in transduction pathways that regulate hematopoiesis and immune cell function. The Janus kinase (JAK)–signal trans...
Synonyms: PF-04965842Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsVoxelotor
go.drugbank.com/drugs/DB14975ApprovedVoxelotor is a novel hemoglobin S polymerization inhibitor for the treatment of sickle cell disease. This is a genetically inherited condition most prevalent in the Middle East, Africa, and certain parts of India. Sickle cell disease can...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 SubstratesRelacorilant
go.drugbank.com/drugs/DB14976ApprovedInvestigationalRelacorilant is a first-in-class, selective glucocorticoid receptor antagonist. Originally investigated to manage the metabolic and endocrinologic complications of hypercortisolism, such as Cushing’s syndrome, its clinical utility has pi...
Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP2C8 InducersCasimersen
go.drugbank.com/drugs/DB14984ApprovedInvestigationalDuchenne muscular dystrophy (DMD) is an X-linked recessive allelic disorder characterized by a lack of functional dystrophin protein, which leads to progressive impairment of ambulatory, pulmonary, and cardiac function and is invariably ...
Categories: Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C9 InhibitorsDifamilast
go.drugbank.com/drugs/DB14987ApprovedInvestigationalAtopic dermatitis is a chronic and fluctuating pruritic inflammatory skin condition characterized by pruritic eczema and is also marked by exacerbations and remissions. This skin disease occurs most frequently in children and can have an...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 InducersAvacopan
go.drugbank.com/drugs/DB15011ApprovedInvestigationalAnti-neutrophil cytoplasmic (auto)antibody (ANCA)-associated vasculitis (AAV) is a rare (estimated incidence of 3 cases per 100,000 per year) form of "pauci-immune" systemic small-vessel vasculitis typified by the presence of ANCAs in th...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesAprocitentan
go.drugbank.com/drugs/DB15059ApprovedInvestigationalAprocitentan is a dual antagonist of endothelin receptors A and B used for treatment-resistant hypertension. It is the active metabolite of macitentan. Approximately 10-15% of patients with hypertension have resistant hypertension, defin...
Categories: P-glycoprotein substrates, Cytochrome P-450 CYP2C18 InhibitorsPemigatinib
go.drugbank.com/drugs/DB15102ApprovedInvestigationalPemigatinib is a small molecule kinase inhibitor with antitumour activity. It works by inhibiting fibroblast growth factor receptors (FGFRs), which are receptor tyrosine kinases that activate signalling pathways in tumour cells. FGFRs ga...
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsTelisotuzumab vedotin
go.drugbank.com/drugs/DB15104ApprovedInvestigationalTelisotuzumab vedotin is an antibody-drug conjugate comprising telisotuzumab, a c-Met-directed humanized IgG1κ monoclonal antibody, conjugated to monomethyl auristatin E (MMAE), a small molecule microtubule-disrupting agent, via a protea...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsFluciclovine
go.drugbank.com/drugs/DB15237InvestigationalFluciclovine is under investigation in clinical trial NCT03036943 (Fluciclovine (18F) Imaging of Breast Cancer).
Categories: P-glycoprotein inhibitors